• About
  • Blog
  • Podcast
  • Speaking
  • Events
  • Services
  • Contact

FatAlpha

Investing website that displays stock ideas, opinions and my strategies.

You are here: Home / Blog / This Magic Formula Stock is Up 15%+ Pre-Open!

This Magic Formula Stock is Up 15%+ Pre-Open!

March 8, 2018 By Sophocles Sophocleous

I’m a fan of using screens to scan the universe for opportunities.  One very popular screen is Joel Greenblatt’s ‘Magic Formula’ which he talks about in his best selling book “The Little Book that Beats the Market”.  Express Scripts (ESRX) is one of the stocks given by the screen and is up more than 15% before the market opens today.  This is because it was just announced that Cigna (CI) has plans to buy the company in a cash and stock deal worth $52 billion (excluding debt).  Specifically, the terms of the deal are that ESRX shareholders receive $48.75 in cash and 0.2434 shares for a value of $96.03 as per yesterday’s CI closing price.  Quite a bump up from $73.42 that ESRX was trading at yesterday.  Merger arbitrage traders may want to put this on their watchlist as there is potential 10% gain according to entry prices.  This can be achieved by buying ESRX and shorting CI (for example, long 100 shares in ESRX and short 24 shares in CI).  So if the deal closes within a year, then the trader can make around 10%, however, it should be noted that some risk is involved.  The deal may not get approved by the shareholders or the Department of Justice may try to block it.  If that happens ESRX will drop and CI will rise and the trader will end up with a losing position.  I believe there is a good chance the deal will go through.  To read more see the WSJ article.

Back to the Magic Formula.  This screen is a ranking system using ‘return on capital’ and ‘earnings yield’.  Using Greenblatt’s definitions I re-created the screen.  For specifics regarding the calculations please scroll to the bottom of the post.  In the first table below you can find the top 50 ranked stocks in alphabetical order.  Go through the list.  Perhaps you will find the next company to be acquired 😉

As you may have noticed several companies are small or lack trading liquidity.  So I ran the screen again, but I added an additional filter.  All the stock in the table below trade an average of $2 million worth a day based on the average trading activity over the last 3 months.

Screens can be a great starting point but not a substitute for research.  I am sure there are value traps in these tables but also opportunities.  I hope the above helps and wish you the best of luck!

 

 

Some points regarding the calculations:

  • Universe:  All shares whose primary security is in the United States.  Excluding receipts, financials, utilities, and managed care.  Also excluded are stocks with a market cap less than $50m or with $0 revenue.
  • Return on capital = EBIT / (Capital Employed – Short-term debt – Excess Cash)
    • Capital Employed = Net Fixed Assets + Current Assets – Current Liabilities
    • This approach was used in order to best replicate Greenblatt which uses Net Working Capital.  It’s a workaround based on the data I have access to.
  • Earnings yield = EBIT / adjusted Enterprise Value
    • adjusted Enterprise Value = Enterprise Value + Underfunded Pension Liabilities

Share this:

  • Tweet
  • Reddit
  • WhatsApp
  • Pocket
  • Email
  • Print

Like this:

Like Loading...

Filed Under: Blog, Stock Screens Tagged With: ESRX

Free Insights & Substack

Charlie Munger quotes

"Avoid working directly under somebody you don't admire and don't want to be like."

Events

Disclaimer

fatalpha.com is not operated by a broker, a dealer, a registered investment adviser, or a regulated entity. Under no circumstances does any information posted represent a recommendation to buy or sell a security. In no event shall fatalpha.com, Sophocles Sophocleous, FATALPHA LTD, or any affiliates or associates be liable to any member or guest for any damages of any kind arising out of the use of any content available on the website. Past performance is a poor indicator of future performance. All the information on this site and any related materials is not intended to be, nor does it constitute investment advice or recommendations. All materials and information you obtain here are exclusively for informational purposes and does not constitute an offer or solicitation to provide any investment services to investors based in the U.S. or elsewhere.

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Recent Posts

  • San Juan Royalty Trust with Brian Anast
  • 7+ Stock Ideas
  • ASSA with Pon Van Compernolle
  • ASML: The picks and shovels of chips
  • 1st FatAlpha Value (Asia)

Disclaimer

fatalpha.com is not operated by a broker, a dealer, a registered investment adviser, or a regulated entity. Under no circumstances does any information posted represent a recommendation to buy or sell a security. In no event shall fatalpha.com, Sophocles Sophocleous, FATALPHA LTD, or any affiliates or associates be liable to any member or guest for any damages of any kind arising out of the use of any content available on the website. Past performance is a poor indicator of future performance. All the information on this site and any related materials is not intended to be, nor does it constitute investment advice or recommendations. All materials and information you obtain here are exclusively for informational purposes and does not constitute an offer or solicitation to provide any investment services to investors based in the U.S. or elsewhere.

Search

Privacy Policy | Cookies Policy | Disclaimer |  Archive

Sophocles Sophocleous

A Fulbright scholar and Chartered Financial Analyst, has been active in the global financial markets since 1999. This website displays his personal thoughts and views. Read More…

Copyright © 2025 · FatAlpha · All rights reserved

*** Free Insights ***
Free stock ideas
Videos of idea discussions
Free substack included Unsubscribe any time
By subscribing, you give us permission to send you our monthly letter. We will NOT be in contact with you in any other way. You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at info@fatalpha.com. We will treat your information with respect. For more information about our privacy practices please visit our website. By providing your email and subscribing, you agree that we may process your information in accordance with these terms. We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.
%d